US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024
Denmark’s Commit Biologics, a specialist in the activation of the complement system to treat cancer and autoimmune disease, has announced the appointment of Mikkel Wandahl Pedersen as chief scientific officer (CSO). 15 October 2024
French biotech Innate Pharma has appointed Jonathan Dickinson as its new chief executive (CEO) and chairman of the executive board, effective November 1, 2024. 14 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
ViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announces the appointment of Nicholas Ostrout, as vice president of corporate development and strategy. 7 October 2024
Boston, USA-based next-generation oncology company Scorpion Therapeutics says that Dr Axel Hoos will join the company as its new chief executive, effective August 2021. 8 July 2021
Dutch specialty pharma company Pharming Group said today it has appointed Anurag Relan as chief medical officer (CMO), effective immediately, and Robert Friesen as chief scientific officer, effective from August 1, 2021. 18 June 2021
Germany’s Merck KGaA is further pushing its science and technology based strategic growth trajectory with two appointments to key senior leadership positions on Group level. In both cases internal candidates will be promoted which underlines the high quality of Merck’s top talent pipeline. 1 June 2021
Specialty UK pharma company Shield Therapeutics, with a focus on addressing iron deficiency with its lead product Feraccru/Accrufer (ferric maltol), today announced that Greg Madison has been appointed as chief executive, with effect from Tuesday, June 1, 2021. 28 May 2021
Capsida Biotherapeutics, a US biotech creating a new class of targeted gene therapies using its adeno-associated virus (AAV) engineering and cargo development platform, has named Swati Tole as the company’s first chief medical officer. 12 May 2021
Catherine Owen, senior vice president of major markets at Bristol Myers Squibb, provides an Expert View on why increasing female representation on corporate boards isn’t just a numbers game. Women bring diverse perspectives that are needed more than ever. 7 May 2021
Eikon Therapeutics, a pioneer in live-cell super-resolution microscopy and engineering for drug discovery, today announced that it has closed a $148 million Series A financing led by The Column Group with participation from Foresite Capital, Innovation Endeavors and Lux Capital. 5 May 2021
The European Commission (EC) has granted marketing authorization to ADV7103 (potassium citrate/potassium hydrogen carbonate), proposed trade name Sibnayal, for the treatment of distal renal tubular acidosis (dRTA), says French biotech Advicenne. 4 May 2021
Krakow, Poland-based oncology specialist Ryvu Therapeutics today announced that Vatnak Vat-Ho has joined the company as chief business officer. 26 April 2021
GlaxoSmithKline, the majority shareholder of Galvani Bioelectronic, today announced the termination of Moncef Slaoui as chairman of the Galvani board of directors, effective immediately. 24 March 2021
British clinical stage drug development company Evgen Pharma today announced that Helen Kuhlman will be joining the company as chief business officer, effective April 1, 2021. 22 March 2021
US pharma giant Merck & Co yesterday revealed that Michael Nally, chief marketing officer, Human Health, will leave the company at the end of March, in order to take up a leadership opportunity with another company. 18 March 2021